CA
NZ
UK
AU
IND
US
…
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
BioStem Technologies, Inc. is an OTCQB-listed company that appears to operate in regenerative medicine and stem cell technologies, but public disclosure about its operations and pipeline is limited. Long-term growth drivers for the sector include aging populations, rising demand for regenerative therapies, and scientific advances, and investors may find upside if the company advances programs, secures partnerships, or obtains funding.
Key risks are limited transparency, constrained financial resources and low liquidity, an early-stage pipeline with regulatory and clinical uncertainty, and dilution from future financings.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | 30.61M | -8.48M | -7.11M | -1.41M | -2.37M |
| Minority interest | - | 0.00M | 0.04M | -0.03M | -0.02M |
| Net income | 31.88M | -8.48M | -7.07M | -1.45M | -2.39M |
| Selling general administrative | 254.75M | 22.63M | 10.43M | 4.19M | 3.09M |
| Gross profit | 288.08M | 15.42M | 5.99M | 2.87M | 1.25M |
| Reconciled depreciation | 0.29M | 0.23M | 0.24M | 0.28M | 0.24M |
| Ebit | - | - | -4.68M | -1.61M | - |
| Ebitda | - | - | -6.40M | -0.60M | -1.59M |
| Operating income | 31.20M | -7.78M | -4.68M | -1.61M | -1.84M |
| Interest expense | 0.59M | 0.70M | 0.47M | 0.53M | 0.53M |
| Tax provision | -1.27M | 0.00M | - | - | 0.00M |
| Interest income | - | - | - | - | 0.00M |
| Net interest income | -0.59M | -0.70M | -0.47M | -0.53M | -0.53M |
| Total revenue | 301.83M | 16.69M | 6.88M | 4.34M | 2.52M |
| Total operating expenses | 270.63M | 24.46M | 11.56M | 5.95M | 4.36M |
| Cost of revenue | 13.75M | 1.26M | 0.88M | 1.47M | 1.27M |
| Total other income expense net | - | -0.00M | -1.96M | 0.72M | - |
| Net income from continuing ops | 31.88M | -8.48M | -7.11M | -1.41M | -2.37M |
| Net income applicable to common shares | - | - | -7.07M | -1.45M | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 140.38M | 14.56M | 3.47M | 2.67M | 2.67M |
| Intangible assets | 0.22M | 0.35M | 0.36M | 0.21M | - |
| Other current assets | 2.87M | 0.33M | 0.28M | 0.04M | -0.00M |
| Total liab | 99.50M | 15.54M | 7.42M | 8.47M | 8.30M |
| Total stockholder equity | 40.88M | -0.98M | -4.08M | -5.96M | -5.80M |
| Other current liab | 0.71M | 0.29M | 0.16M | 0.34M | 0.19M |
| Common stock | - | - | 0.01M | 0.01M | - |
| Capital stock | 0.02M | 0.02M | 0.01M | 0.01M | 3.68M |
| Retained earnings | -13.74M | -45.00M | -37.02M | -29.95M | -28.20M |
| Other liab | - | - | 0.05M | 0.12M | - |
| Good will | 0.24M | 0.24M | 0.24M | 0.24M | 0.47M |
| Other assets | - | - | -0.00M | - | - |
| Cash | 22.83M | 0.24M | 0.77M | 0.34M | 0.10M |
| Total current liabilities | 99.17M | 15.26M | 6.33M | 6.54M | 6.80M |
| Net debt | - | 4.47M | 4.30M | 4.46M | 5.21M |
| Short long term debt | 3.96M | 4.45M | 4.04M | 3.00M | 3.99M |
| Property plant equipment | - | - | 1.37M | 1.28M | - |
| Total current assets | 133.76M | 12.60M | 1.49M | 0.94M | 0.85M |
| Net tangible assets | - | - | -4.68M | -6.41M | - |
| Net receivables | 104.98M | 11.37M | 0.04M | 0.30M | 0.01M |
| Long term debt | 0.15M | 0.27M | 1.03M | 1.80M | 1.32M |
| Inventory | 1.82M | 0.66M | 0.40M | 0.26M | 0.57M |
| Accounts payable | 5.29M | 1.03M | 0.57M | 0.65M | 0.61M |
| Non current assets total | 6.61M | 1.96M | 1.98M | 1.73M | 1.82M |
| Capital lease obligations | 0.29M | 0.01M | 0.02M | 0.03M | 0.31M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -1.68M | -0.21M | -0.47M | -0.01M | 0.00M |
| Change to liabilities | - | - | -0.08M | -0.02M | - |
| Total cashflows from investing activities | - | - | -0.47M | -0.01M | - |
| Net borrowings | -0.85M | 0.80M | 0.52M | 0.23M | - |
| Total cash from financing activities | -0.21M | 3.18M | 0.57M | 0.36M | 0.54M |
| Change to operating activities | - | - | -0.04M | 0.61M | - |
| Net income | 31.88M | -7.86M | -7.07M | -1.45M | -2.39M |
| Change in cash | 22.59M | -0.53M | 0.43M | 0.24M | -0.04M |
| Begin period cash flow | 0.24M | 0.77M | 0.34M | 0.10M | 0.14M |
| End period cash flow | 22.83M | 0.24M | 0.77M | 0.34M | 0.10M |
| Total cash from operating activities | 24.48M | -3.50M | -1.64M | -0.11M | -0.58M |
| Issuance of capital stock | - | 2.38M | 0.05M | 0.12M | - |
| Depreciation | 0.29M | 0.23M | 0.24M | 0.28M | 0.24M |
| Change to inventory | -1.17M | -0.26M | -0.14M | 0.21M | -0.01M |
| Change to account receivables | -93.78M | -11.33M | 0.26M | -0.29M | 0.07M |
| Sale purchase of stock | -0.00M | 0.00M | - | - | - |
| Change to netincome | - | - | 5.19M | 0.54M | - |
| Capital expenditures | 0.43M | 0.21M | 0.24M | 0.04M | 0.00M |
| Change in working capital | -12.01M | -3.08M | 0.01M | 0.52M | 0.92M |
| Stock based compensation | 6.66M | 5.76M | 4.90M | 0.40M | - |
| Other non cash items | 0.46M | 1.46M | 0.32M | 0.79M | 0.38M |
| Free cash flow | 24.05M | -3.71M | -2.11M | -0.15M | -0.58M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BSEM BioStem Technologies, Inc. Common Stock |
-0.01 0.89% |
1.12 | 5.27 | 13.62 | 1.64 | 1.52 | 0.18 | 3.34 |
| NVO Novo Nordisk A/S |
1.09 2.72% |
41.41 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.78 0.69% |
550.87 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
15.61 1.73% |
919.96 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
4901 Northwest 17th Way, Fort Lauderdale, FL, United States, 33309
954 380 8342
| Name | Title | Year Born |
|---|---|---|
| Mr. Jason Matuszewski | Interim Chairman, CEO, Pres & Sec. | NA |
| Mr. Michael Fortunato CPA | Chief Financial Officer | NA |
| Mr. Andrew Vanvurst | COO & Director | NA |
| Dr. David M. Woynarowski | Chief Medical Officer | NA |
| Mr. Larry Jones | Chief Revenue Officer | NA |
| Dr. Irmgard Huber M.D. | International Medical Advisor & Interim Chief Medical Officer | NA |
| Mr. Jason Matuszewski | CEO, President, Director & Secretary | NA |
| Mr. Shawn F. McCarrey | Chief Commercial Officer | 1958 |
| Mr. Jason V. Matuszewski | CEO, President, Director & Secretary | 1986 |
| Mr. Michael A. Fortunato CPA | Chief Financial Officer | 1967 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.88%
Communication Services
+1.14%
Consumer Cyclical
+1.04%
Consumer Defensive
+0.57%
Energy
+0.50%
Financial Services
+0.81%
Financials
+0.24%
Healthcare
+1.35%
Industrials
+1.54%
Real Estate
+0.24%
Technology
+2.32%
Utilities
+0.48%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
-4.40%
Please wait processing your request...